Liver News and Research

RSS

Novel strategy to build molecular probes may lead to development of new cancer drugs

Chemical engineers at UC Santa Barbara expect that their new process to create molecular probes may eventually result in the development of new drugs to treat cancer and other illnesses.

7 Apr 2011

Navigator-3 gene plays a key role in liver development

Scientists of the Max Delbr-ck Center for Molecular Medicine Berlin-Buch have demonstrated for the first time that a gene regulating neuronal cell migration during embryogenesis also plays a role in the development of the liver.

7 Apr 2011

Supplements are less well regulated than drugs and may have side effects, drug interactions and toxicities

Vitamins, herbs and other dietary supplements are sold as natural alternatives to pharmaceuticals and many people turn to them in an attempt to improve their health. Others seek supplements to lose weight or after hearing that they can help with serious medical conditions.

7 Apr 2011

NIH awards HemoShear with Phase I SBIR grant to develop rodent liver system

HemoShear, LLC, is pleased to announce that it was awarded a Phase 1 Small Business Innovation Research grant from the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health.

7 Apr 2011

Results of study evaluating potential inhibitory effects of PPIs on Plavix presented at ACC 2011

Takeda Pharmaceuticals North America, Inc. announced the presentation of new study results, which evaluated the potential inhibitory effects of certain proton pump inhibitors (PPIs) on Plavix (clopidogrel bisulfate). The results showed that in healthy subjects, clopidogrel's active metabolite and inhibition of platelet function were reduced less by the co-administration of clopidogrel with dexlansoprazole or lansoprazole, rather than esomeprazole.

6 Apr 2011

AMPK suppression and SREBP activation are root cause of fatty liver and hyperlipidemia in type 2 diabetes

Researchers from Boston University School of Medicine, including Yu Li, PhD, and other colleagues, have demonstrated that a nutrient sensing pathway is involved in the disruption of cellular lipid homeostasis in obese and insulin resistant mice fed a diet high in fat and sucrose.

6 Apr 2011

J&JPRD announces rivaroxaban Phase 3 trial results against venous thromboembolism

Johnson & Johnson Pharmaceutical Research & Development, L.L.C., today announced results from the MAGELLAN Phase 3 trial evaluating the investigational oral anticoagulant rivaroxaban for the prevention of venous thromboembolism in hospitalized patients with acute medical illnesses.

6 Apr 2011

Scientists uncover SREBP-2 role in autophagy and cholesterol generation

Not all cholesterol is bad. Every cell requires it for growth - they either have to get cholesterol somewhere or they die. In a new study published April 6 in the journal Cell Metabolism, researchers from Sanford-Burnham Medical Research Institute and their collaborators found that a protein sensor known to balance cholesterol sources can also access a previously underappreciated cellular fat storage depot.

6 Apr 2011

Genzyme, Isis present mipomersen phase 3 study data in severe heFH at ACC meeting

Genzyme Corp., a subsidiary of sanofi-aventis Group, and Isis Pharmaceuticals Inc. announced today that data from two phase 3 studies of mipomersen in patients who had high cholesterol levels while on lipid-lowering therapy were presented at the American College of Cardiology's 60th Annual Scientific Session.

6 Apr 2011

South Sudan health workers face worst Kala-azar outbreak

South Sudan is facing the worst outbreak of Kala-azar in the past 10 years as health workers from Servant's Heart Relief race against the clock to stop the spread of the deadly disease.

5 Apr 2011

Scientists identify gene influencing levels of alcohol consumption

Scientists have identified a gene that appears to play a role in regulating how much alcohol people drink, in a study of over 47,000 people published today in Proceedings of the National Academy of Sciences.

5 Apr 2011

Synta presents ganetespib and elesclomol study data in cancer at AACR meeting

Synta Pharmaceuticals Corp. today presented five posters at the American Association for Cancer Research 102nd Annual Meeting. Three posters reported results from studies of ganetespib, and two posters reported results from studies of elesclomol, a small-molecule mitochondria metabolism inhibitor.

5 Apr 2011

American Cancer Society awards 85 institutions with $49,213,000 for new research, training

The American Cancer Society, the largest non-government, not-for-profit funding source of cancer research in the United States, has awarded 132 national research and training grants totaling $49,213,000 to 85 institutions nationwide in the second of two grants cycles for 2011.

5 Apr 2011

Jennerex, Transgene present JX-594 Phase 1 and 2 study data in liver cancer at EASL meeting

Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic products for cancer, and Transgene,a bio-pharmaceutical company specialized in the development of immunotherapeutic products, today announced that new data from Phase 1 and 2 clinical studies of JX-594 were presented in an oral presentation at the 46th Annual Meeting of the European Association for the Study of the Liver over the weekend at the Internationales Congress Centrum in Berlin, Germany.

5 Apr 2011

New computer-based system can distinguish similar secondary tumours

A new computer-based system discussed in the International Journal of Healthcare Technology and Management can distinguish between apparently similar secondary tumours and allow a cancer specialist to trace the metastases back to the site of the original cancer in the patient's body.

5 Apr 2011

Abbott and Enanta's ABT-450/r Phase 2 study results against HCV presented at EASL meeting

Abbott and Enanta Pharmaceuticals today announced 12-week results from a Phase 2 study of ABT-450/r, an investigational, oral protease inhibitor being developed for the treatment of hepatitis C infection.

4 Apr 2011

Study demonstrates in vitro infection and HEV replication in human hepatocytes

Groundbreaking data presented today demonstrates, for the first time, in vitro infection and replication of swine hepatitis E virus in human hepatocytes.

4 Apr 2011

BMY announces PEG-Interferon lambda plus ribavirin Phase IIb trial results against HCV

Bristol-Myers Squibb Company today announced results from the Phase IIb EMERGE clinical trial, in which treatment with the investigational compound PEG-Interferon lambda and ribavirin achieved higher rates of rapid virologic response in genotypes 1, 2, 3, and 4, and complete early virologic response in genotypes 1 and 4 than the standard regimen of PEG-Interferon alfa and ribavirin in treatment-naïve patients chronically infected with hepatitis C.

4 Apr 2011

New data: Quadruple therapy can effectively treat patients with HCV

Exciting new data presented today at the International Liver CongressTM 2011 show that quadruple therapy in chronic hepatitis C patients suppressed the emergence of resistant variants and resulted in a 100% rate of sustained virological response - undetectable HCV RNA - 12 weeks after treatment.

4 Apr 2011

New data finds PegIFN-lambda shows RVR in HCV patients with improved safety, tolerability

Highly exciting new data presented today at the International Liver Congress found Pegylated Interferon-lambda shows superior virological response in HCV patients of genotypes 1-4, with improved safety and tolerability, compared to Pegylated Interferon-alpha, the current standard of care in chronic HCV.

4 Apr 2011

Liver News and Research

Novel strategy to build molecular probes may lead to development of new cancer drugs

Navigator-3 gene plays a key role in liver development

Supplements are less well regulated than drugs and may have side effects, drug interactions and toxicities

NIH awards HemoShear with Phase I SBIR grant to develop rodent liver system

Results of study evaluating potential inhibitory effects of PPIs on Plavix presented at ACC 2011

AMPK suppression and SREBP activation are root cause of fatty liver and hyperlipidemia in type 2 diabetes

J&JPRD announces rivaroxaban Phase 3 trial results against venous thromboembolism

Scientists uncover SREBP-2 role in autophagy and cholesterol generation

Genzyme, Isis present mipomersen phase 3 study data in severe heFH at ACC meeting

South Sudan health workers face worst Kala-azar outbreak

Scientists identify gene influencing levels of alcohol consumption

Synta presents ganetespib and elesclomol study data in cancer at AACR meeting

American Cancer Society awards 85 institutions with $49,213,000 for new research, training

Jennerex, Transgene present JX-594 Phase 1 and 2 study data in liver cancer at EASL meeting

New computer-based system can distinguish similar secondary tumours

Abbott and Enanta's ABT-450/r Phase 2 study results against HCV presented at EASL meeting

Study demonstrates in vitro infection and HEV replication in human hepatocytes

BMY announces PEG-Interferon lambda plus ribavirin Phase IIb trial results against HCV

New data: Quadruple therapy can effectively treat patients with HCV

New data finds PegIFN-lambda shows RVR in HCV patients with improved safety, tolerability

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News